Streamlining Radioembolization for CCC and Metastatic Liver Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage. However, some microspheres may drain into hepatic veins and reach the lungs, risking radiation pneumonitis. Pre-procedural evaluation with angiography and nuclear imaging (MAA scan with SPECT/CT) is required to calculate lung shunt fraction (LSF). TARE is contraindicated if LSF \>20%, and may be used with caution if LSF is 10-20%. Findings associated with high LSF include large tumors, hepatic vein invasion, TIPS, and dysmorphic intratumoral vessels. In contrast, small or medium sized (\<7 cm) cholangiocarcinoma or metastatic liver cancers without hepatic vein invasion or dysmorphic vessels show consistently low LSF (\<5%). Over 10 years at SNUH, no cases of radiation pneumonitis have been observed in such patients. Therefore, "streamlining TARE" omits pre-procedural nuclear imaging for this group to reduce procedural delays, reserving nuclear imaging for patients who need it most. SIR-Spheres (SIRTEX) facilitate single-session TARE as they are provided in a bulk vial, unlike TheraSphere which requires advance preparation based on dosimetry. Protocol Overview : Procedure: Same-day angiography, cone-beam CT, and TARE using SIR-Spheres. Dosimetry: Lung shunt fraction is assumed as 5%, estimated lung dose is capped at 10 Gy. Tumor dose goal: 80\~400 Gy (around 250Gy)(single-compartment MIRD), or 300 \~ 1000 Gy (multi-compartment MIRD). minimal tumor dose by partition dosimetry : 100Gy Software: Simplicit90Y for planning, Y90 PET/CT the next day for post-treatment dosimetry. Follow-up: 1 year; additional treatments follow institutional guidelines. This streamlined approach maximizes efficiency while maintaining safety in selected patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 19 lat i więcej
- •Nowotwór wątroby przerzutowy lub rak przewodów żółciowych
- •Największy guz nie większy niż 7 cm, liczba guzów do 5
- •Wystarczająca ilość zdrowej tkanki wątroby (ponad 30% objętości)
- •Dobry ogólny stan zdrowia (skala ECOG 0-1)
- •Prawidłowe wyniki badań krwi (wątroba, nerki, liczba krwinek)
- •Spodziewana przeżywalność co najmniej 3 miesiące
- •Negatywny test ciążowy u kobiet w wieku rozrodczym
✗ Disqualifies
- •Naciek guza do żyły wątrobowej
- •Nieprawidłowe naczynia krwionośne w guzie większe niż 3 mm
- •Przeszczepiony shunt portalno-systemowy (TIPS)
- •Tromboза (skrzep) w głównej żyle wrotnej
- •Poważne choroby płuc (rozedma, zmiana zanikowa) mogące prowadzić do śmierci
- •Wcześniejsza stent w przewodach żółciowych lub połączenie przetoki
- •Ciężka alergia na substancje radiologiczne
- •Bezwzględne przeciwwskazania do zabiegu angiografii
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Locations (4)
National Cancer Center
Goyang-si, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance hospital
Seoul, South Korea
Trial contact
Hyo-Cheol Kim, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.